ArriVent BioPharma, Inc. AVBP EBIT

EBIT at other companies

Johnson & JohnsonJNJ

$7.14B+7.4%

Oric Pharmaceuticals, Inc.ORIC

-$39.62M-21.1%

Syndax PharmaceuticalsSNDX

-$34.2M+59.2%

Inhibrx Biosciences, Inc.INBX

-$30.93M+27.9%

Bicara TherapeuticsBCAX

-$60.24M-44.2%

ImmunomeIMNM

-$59.33M-32.9%

FAQ

What is ArriVent BioPharma, Inc.'s EBIT?

ArriVent BioPharma, Inc. (AVBP) reported EBIT of -$46.11M in Q1 2026.

How has ArriVent BioPharma, Inc.'s EBIT changed year-over-year?

ArriVent BioPharma, Inc.'s EBIT increased by 30.9% year-over-year, from -$66.77M to -$46.11M.

What is the long-term trend for ArriVent BioPharma, Inc.'s EBIT?

Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s EBIT has grown at a 54.3% compound annual growth rate (CAGR), from -$74.59M to -$177.53M.

What does EBIT mean?

Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.